333 related articles for article (PubMed ID: 12191639)
21. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
22. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
[TBL] [Abstract][Full Text] [Related]
23. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
[TBL] [Abstract][Full Text] [Related]
24. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract][Full Text] [Related]
25. BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer.
Velázquez-Hernández N; Reyes-Romero MA; Barragán-Hernández M; Guerrero-Romero F; Rodríguez-Moran M; Aguilar-Durán M; Lazalde Medina B
Genet Mol Res; 2015 Jun; 14(2):6094-100. PubMed ID: 26125810
[TBL] [Abstract][Full Text] [Related]
26. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity.
Filippova GN; Qi CF; Ulmer JE; Moore JM; Ward MD; Hu YJ; Loukinov DI; Pugacheva EM; Klenova EM; Grundy PE; Feinberg AP; Cleton-Jansen AM; Moerland EW; Cornelisse CJ; Suzuki H; Komiya A; Lindblom A; Dorion-Bonnet F; Neiman PE; Morse HC; Collins SJ; Lobanenkov VV
Cancer Res; 2002 Jan; 62(1):48-52. PubMed ID: 11782357
[TBL] [Abstract][Full Text] [Related]
27. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
[TBL] [Abstract][Full Text] [Related]
28. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.
Pugacheva EM; Teplyakov E; Wu Q; Li J; Chen C; Meng C; Liu J; Robinson S; Loukinov D; Boukaba A; Hutchins AP; Lobanenkov V; Strunnikov A
Epigenetics Chromatin; 2016; 9(1):35. PubMed ID: 27588042
[TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
[TBL] [Abstract][Full Text] [Related]
31. CTCFL (BORIS) mRNA Expression in a Peripheral Giant Cell Granuloma of the Oral Cavity.
Zambrano-Galván G; Reyes-Romero M; Bologna-Molina R; Almeda-Ojeda OE; Lemus-Rojero O
Case Rep Dent; 2014; 2014():792615. PubMed ID: 25114808
[TBL] [Abstract][Full Text] [Related]
32. A Common Polymorphism within the IGF2 Imprinting Control Region Is Associated with Parent of Origin Specific Effects in Infantile Hemangiomas.
Schultz B; Yao X; Deng Y; Waner M; Spock C; Tom L; Persing J; Narayan D
PLoS One; 2015; 10(10):e0113168. PubMed ID: 26496499
[TBL] [Abstract][Full Text] [Related]
33. Dose-dependent activation of putative oncogene SBSN by BORIS.
Gaykalova D; Vatapalli R; Glazer CA; Bhan S; Shao C; Sidransky D; Ha PK; Califano JA
PLoS One; 2012; 7(7):e40389. PubMed ID: 22792300
[TBL] [Abstract][Full Text] [Related]
34. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
Kang Y; Hong JA; Chen GA; Nguyen DM; Schrump DS
Oncogene; 2007 Jun; 26(30):4394-403. PubMed ID: 17260018
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF.
De La Rosa-Velázquez IA; Rincón-Arano H; Benítez-Bribiesca L; Recillas-Targa F
Cancer Res; 2007 Mar; 67(6):2577-85. PubMed ID: 17363576
[TBL] [Abstract][Full Text] [Related]
36. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma.
He J; Huang Y; Liu Z; Zhao R; Liu Q; Wei L; Yu X; Li B; Qin Y
Gene; 2017 Sep; 629():29-34. PubMed ID: 28764977
[TBL] [Abstract][Full Text] [Related]
37. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.
Fiorentino FP; Macaluso M; Miranda F; Montanari M; Russo A; Bagella L; Giordano A
Mol Cancer Res; 2011 Feb; 9(2):225-33. PubMed ID: 21325284
[TBL] [Abstract][Full Text] [Related]
38. Critical DNA binding interactions of the insulator protein CTCF: a small number of zinc fingers mediate strong binding, and a single finger-DNA interaction controls binding at imprinted loci.
Renda M; Baglivo I; Burgess-Beusse B; Esposito S; Fattorusso R; Felsenfeld G; Pedone PV
J Biol Chem; 2007 Nov; 282(46):33336-33345. PubMed ID: 17827499
[TBL] [Abstract][Full Text] [Related]
39. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
40. CTCF and CTCFL in cancer.
Debaugny RE; Skok JA
Curr Opin Genet Dev; 2020 Apr; 61():44-52. PubMed ID: 32334335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
